Gui‐Qi Zhu

机构：Ministry of Education of the People's Republic of China, Chinese Academy of Medical Sciences & Peking Union Medical College, Fudan University, Cancer Institute (WIA), Dana-Farber Cancer Institute, Zhejiang Hospital, Zhongshan Hospital · ORCID：0000-0001-5089-6923

发表论文 96 篇 · 总被引 2914 次 · h-index 32

代表论文

• Targeting SRSF10 might inhibit M2 macrophage polarization and potentiate anti‐PD‐1 therapy in hepatocellular carcinoma (2024 · 癌症：英文版 · 被引 171)
• Targeting IRG1 reverses the immunosuppressive function of tumor-associated macrophages and enhances cancer immunotherapy (2023 · Science Advances · 被引 152)
• Splicing factor SRSF1 promotes breast cancer progression via oncogenic splice switching of PTPMT1 (2021 · Journal of Experimental & Clinical Cancer Research · 被引 118)
• Development of a deep pathomics score for predicting hepatocellular carcinoma recurrence after liver transplantation (2023 · Hepatology International · 被引 58)
• Cancer-associated fibroblasts contributed to hepatocellular carcinoma recurrence and metastasis via CD36-mediated fatty-acid metabolic reprogramming (2024 · Experimental Cell Research · 被引 44)
• Methyltransferase like 3 inhibition limits intrahepatic cholangiocarcinoma metabolic reprogramming and potentiates the efficacy of chemotherapy (2023 · Oncogene · 被引 44)